Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab vs Nivolumab in Untreated Metastatic or Unresectable Melanoma
2017-003583-12Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Relatlimab + Nivolumab FDC with Nivolumab monotherapy (2 arms). Started Feb 2018; status: active.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-003583-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003583-12.